Zhejiang Hengyi Pharmaceutical Technology

Zhejiang Hengyi Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Hangzhou, China, dedicated to the discovery and development of innovative small molecule drugs. The company focuses on therapeutic areas with significant unmet needs, particularly immunology, dermatology, and oncology. Its lead clinical candidate, HY-0002, is a highly selective Janus kinase 1 (JAK1) inhibitor currently being evaluated in Phase 2 clinical trials for rheumatoid arthritis and atopic dermatitis. Hengyi utilizes its proprietary drug discovery platform to develop differentiated molecules with optimized safety and efficacy profiles. The company is committed to advancing its pipeline through internal research and strategic collaborations to deliver high-quality treatments to the global market.